HeartBeam Announces Public Offering to Fund Cardiac Technology Commercialization and AI Development

HeartBeam Inc. (NASDAQ: BEAT) announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The company stated it intends to use net proceeds from the offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities and support working capital and general corporate purposes. Titan Partners, a division of American Capital Partners, is acting as sole bookrunner for the offering, with the final size and terms subject to market conditions.

The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.

HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.

The announcement signals a significant step in bringing advanced cardiac monitoring technology to market. By securing funding through this public offering, HeartBeam aims to accelerate the deployment of its portable ECG system, which could enable earlier detection of heart conditions outside traditional clinical settings. The focus on AI enhancement suggests the company is working to improve diagnostic accuracy and predictive capabilities, potentially leading to more personalized cardiac care. The development of an extended-wear patch and heart attack detection initiatives indicates a broader strategy to create a comprehensive remote monitoring ecosystem for cardiac patients.

This funding initiative comes at a time when remote patient monitoring and telehealth technologies are gaining increased importance in healthcare delivery. HeartBeam’s technology addresses a critical need for reliable cardiac assessment tools that patients can use in their daily lives, potentially reducing hospital visits and enabling more proactive management of heart conditions. The success of this offering could determine the pace at which these innovations reach patients and healthcare providers, making it a pivotal moment for the company’s growth trajectory in the competitive medical technology sector.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is HeartBeam Announces Public Offering to Fund Cardiac Technology Commercialization and AI Development.

The post HeartBeam Announces Public Offering to Fund Cardiac Technology Commercialization and AI Development appeared first on citybuzz.